Rhythm Published on Phase 2 Study of Setmelanotide for Treatment of Hypothalamic Obesity

 Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment -

- Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 -

https://www.globenewswire.com/news-release/2024/04/29/2871725/0/en/Rhythm-Pharmaceuticals-Announces-Publication-of-Results-from-Phase-2-Study-of-Setmelanotide-for-the-Treatment-of-Hypothalamic-Obesity-in-The-Lancet-Diabetes-Endocrinology.html